Home News & Events Events Workshops Workshops Page tools Share Share Share on LinkedinShare on BlueskyShare on XShare on Facebook Print Search Email Accessibility Workshop NONMEM Introduction Workshop (China Region): Applications in PK/PD Modeling (Mandarin Language) Date 31 July 2026 Time 09:00 - 12:00 Location Online/Virtual Webex Timezone Asia/Shanghai Workshop NONMEM Introduction Workshop (China Region): Applications in PK/PD Modeling (Mandarin Language) Date 3 September 2026 Time 09:00 - 12:00 Location Online/Virtual Webex Timezone Asia/Shanghai Workshop Beginners/Intermediate Online NONMEM/PDx-Pop Workshop Date 22 September 2026 - 23 September 2026 Time 09:00 - 17:00 Location Online/Virtual Webex Timezone America/New York Workshop Advanced Online NONMEM/PDx-Pop Workshop Date 24 September 2026 Time 09:00 - 17:00 Location Online/Virtual Webex Timezone America/New York Workshop New and Advanced Features of NONMEM 7.6 at ACoP 2026 In Person Workshop Date 11 October 2026 Time 08:00 - 17:00 Location Gaylord National Resort & Convention Center, Oxon Hill, Maryland, USA. Timezone America/New York In this section In this section Press releases In the News Mediakit Facts and figures ICON spokespeople Awards Events Industry events ASCO 2026 ISPOR EU 2026 Webinars Workshops Webinars Social media hub Connect with us Contact us Submit proposal request Update Email Preferences Global office locator ICON on social media Related information: Event Webinars Event Industry Events What’s happening in ICON ICON Plc Global clinical development is entering a more connected, data-driven era. While the FDA is piloting real-time clinical trials, other regulatory bodies are advancing AI and digital strategies in different ways, creating... 27 Jul View post View webpage ICON Plc AI can improve speed and scale but trust still requires people. ICON’s Mia Malmenäs emphasizes that human expertise remains essential for interpreting incomplete evidence, evaluating AI outputs, applying regulatory and ... 24 Jul View post View webpage ICON Plc Italy's pharmaceutical traceability system is undergoing one of its most significant transformations in decades. New legislation will introduce a hybrid serialisation model that aligns Italy more closely with EU Falsifi... 24 Jul View post View webpage ICON Plc Patient safety starts long before the first neurologic mAb dose. Indication-specific safety planning and strict patient stratification are vital, from HBV screening in MS to AQP4 status in NMOSD. Read the article to dive... 23 Jul View post View webpage ICON Plc If you've ever searched for pharmacovigilance and wondered what it actually means, you're not alone. While roles like Clinical Research Associate are widely recognised, pharmacovigilance is often less understood. Yet it... 23 Jul View post View webpage ICON Plc Where is Agentic AI creating the greatest value today? Mia Malmenäs, Senior Principal at ICON, highlights that the strongest and most reliable ROI is currently in HTA dossier development and evidence synthesis. AI can a... 22 Jul View post View webpage ICON Plc Earlier this month, colleagues from ICON Mexico came together for our fifth consecutive Blood Donation Campaign. Around 90 colleagues registered to take part, with 37 successfully donating blood following assessment by ... 21 Jul View post ICON Plc The EU’s PPWR is not a standalone regulatory change. It is a strategic transformation that touches the entire product lifecycle. In this article ICON’s Global Labelling & Ad Promotion team outlines practical recommendat... 21 Jul View post View webpage ICON Plc Japan is emerging as a leading destination for regenerative medicine, backed by established regulatory pathways, a large patient population, and one of the world's most comprehensive healthcare data systems. Read our lat... 21 Jul View post View webpage ICON Plc Is your COPD development programme ready for the precision medicine era? From eosinophil-driven patient selection to adaptive trial designs and the integration of real-world evidence, success increasingly depends on pre... 21 Jul View post View webpage ICON Plc Heart failure affects millions of people worldwide and can significantly impact quality of life. Research into new treatment approaches remains critical to improving outcomes and expanding options for patients living wit... 20 Jul View post View webpage ICON Plc Biomarker-based surrogate endpoints can accelerate development timelines – but only when the evidence, pathway and expectations are aligned. In the latest issue of Drug & Device World ICON’s Elizabeth Madichie and Jack ... 20 Jul View post View webpage
